NCT04591431
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients who have bone-only and/or brain-only metastases
https://ClinicalTrials.gov/show/NCT04591431